View
92
Download
0
Category
Preview:
Citation preview
BioRealm SmokeScreen Genotyping Array Looks toBoost Drug Addiction ResearchJul 07, 2015 | Andrew P. Han
CDC/Debora Cartagena via WikiMedia CommonsNEW YORK (GenomeWeb) – BioRealm Research's SmokeScreen Genotyping array for drug andaddiction research is ready for heavy-duty usage in high-throughput studies and will soon be deployedin a genotyping study of over 50,000 samples from a National Institute on Drug Abuse biobank.
Two small business innovation research grants from NIDA funded development of the array, whichanalyzes 1,031 genes related to addiction using 273,493 biomarkers. It also includes the AffymetrixBiobank Array for genome-wide association studies, other markers related to addiction, SNPs related tosmoking and lung cancer, and other markers BioRealm thought might be important, such as loss-of-function markers and pharmacogenetic markers.
In all, researchers can look at 646,247 markers in each well of the 96-well plate.
Monument, Colorado-based BioRealm designed the array as part of a SBIR grant, but the firm involvedAffymetrix early on in the development process.
"We evaluated the Affymetrix Axiom technology and it was a perfect fit for this array," Chris Edlund,bioinformatic principal at BioRealm, told GenomeWeb. The Axiom Biobank Array provides the backboneof the array, he said, and BioRealm went back and forth with Affymetrix for several iterations to come upwith the final design.
"The design goal of the array was to cover all SNPs and genes associated with tobacco addiction aswell as providing genome-wide coverage of multiple populations," including genetic variation found inEuropean, East Asian, and African populations, Affymetrix COO Andy Last told GenomeWeb.
Premium
Affymetrix manufactures the array, which is built to run on the GeneTitan instrument. For the NIDAgenotyping project, RUCDR Infinite Biologics, a unit of Rutgers University's Human Genetics Institute ofNew Jersey, will perform the genotyping.
Last added that Affymetrix will have a role in commercializing the array through its standard commercialchannels.
In addition to designing the array, BioRealm developed the back-end software to process the data. Thebioinformatics package, which runs on Amazon's cloud services, can also take in phenotypicinformation associated with a sample and integrate that with the genotype, Edlund said.
The project started in 2012, when BioRealm won an NIDA-sponsored Phase I SBIR grant to develop agenetic screening tool for research on tobacco dependency. BioRealm Co-founder James Baurley saidthe firm had experience in the array space, having been involved in consulting projects making customIllumina arrays.
"The specifications were loose, so we developed a plan based on the general requirements that theylaid out," Edlund said. "They mentioned a list of 5,000 SNPs that they were interested in. Those 5,000SNPs made it onto the array, but we expanded it to almost 650,000."
In a pilot study conducted during the Phase II grant, the SmokeScreen array was able to identify a genepreviously associated with nicotine metabolism, providing some proof that the tool would be useful inresearch.
Three considerations guided the array design, Edlund said. The firm wanted to provide coverage ofgenes associated with addiction, a genome-wide backbone, and other high-priority SNPs BioRealm hadidentified in the scientific literature. "Once we went to design it, we realized we could add a lot more," hesaid. The firm asked researchers in the field to nominate additional genes and SNPs of interest.
Additions included the National Human Genome Research Institute GWAS catalog and 3,000 SNPsassociated with lung cancer.
The firm has validated the array by genotyping about 800 samples from multiple populations incollaboration with Rutgers, Edlund said. "The arrays performed very well," he said, and BioRealm iscurrently in the process of writing a manuscript that will report the validation statistics.
BioRealm's informatics pipeline first uses Affymetrix's best practices workflows to filter out poorlyperforming SNPs, Edlund said. After the quality control has been performed, it uses Minimac softwarefor imputation. "It's designed to be flexible so that we can spawn up instances as needed," he said.Multiple instances running in parallel on the cloud can allow the software to finish running in a day.
The software also does some simple GWAS statistical analysis, like providing association p-values forSNPs, Edlund said, as well as some more advanced statistics, which he declined to specify.
Researchers can download the data in standard formats, though Edlund said BioRealm's preferredformat is for the PLINK toolset.
"We developed the bioinformatics pipeline to be flexible enough to use with any Affymetrix Axiomarray," Edlund said, including both custom- and fixed-content arrays.
Baurley, the BioRealm Co-founder, said that the firm is currently exploring options to package its
pipeline and analysis services with other Affymetrix Axiom arrays. "Some pieces of it could be modifiedfor other diseases or complex traits," he said.
Filed Under Microarrays & Multiplexing Neurological & Psychological Disorders Informatics
drug abuse genotyping array Affymetrix
! Get Weekly Informatics Updates
Related Articles
Jul 07, 2015
Affymetrix, BioRealm, RUCDR Ally to Genotype NIDA Biobank
Sep 21, 2015
Green Super Rice Project Selects Affymetrix for Genotyping Activities
Jul 30, 2015
Despite Drop in Q2 Genoptying Revenue, Affymetrix CEO Sees AdditionalOpportunities
Oct 08, 2015
Affymetrix Launches Transplant Array, Offering Broad Genomic Coverage andUtility in Other Research
Oct 27, 2015
Affymetrix, Athletigen Push Sports-Focused Genetic Analysis Onto AxiomGenotyping Platform
Jun 09, 2015
Illumina Capitalizes on Cattle Breeders Adopting SNP Chips for GenomicSelection
Privacy Policy. Copyright © 2015 Genomeweb LLC. All Rights Reserved.
Recommended